Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Rigetti Computing: A Quantum Bet Under Pressure

Dieter Jaworski by Dieter Jaworski
November 21, 2025
in AI & Quantum Computing, Analysis, Nasdaq, Tech & Software
0
Rigetti Stock
0
SHARES
85
VIEWS
Share on FacebookShare on Twitter

The quantum computing sector faces a critical test as shares of Rigetti Computing experience significant downward momentum. Following a steep single-day decline exceeding 10% on Thursday, investors are grappling with a fundamental question: is this a necessary market correction for an overvalued technology play, or a unique entry point into a potentially transformative industry?

Institutional Sentiment Shifts

A notable shift in analyst outlook is adding to the selling pressure. Two prominent financial institutions have substantially lowered their price targets for Rigetti. Benchmark adjusted its valuation downward from $50 to $40 per share, while B. Riley Financial made an even deeper cut, reducing its target from $42 to $35. The rationale centers on concerns that the company’s current market valuation appears difficult to justify following recent financial performance.

The third-quarter earnings report revealed a troubling 18% drop in revenue, which settled at just $1.95 million—falling short of the anticipated $2.17 million. This creates a stark contrast with Rigetti’s market capitalization of approximately $7.4 billion, highlighting a significant gap between investor expectations and current commercial performance. This divergence between speculative potential and financial reality is creating substantial headwinds for the stock.

Insider Activity Raises Questions

Compounding investor concerns is a pattern of insider selling that market participants often view as a potential warning signal. Chief Financial Officer Jeffrey A. Bertelsen reported the disposal of approximately 3,700 shares. Additionally, directors Thomas J. Iannotti and Ray O. Johnson collectively divested more than 220,000 shares in recent weeks. Such activity naturally prompts market observers to question whether company insiders possess information that justifies their reduced exposure.

Should investors sell immediately? Or is it worth buying Rigetti?

However, the institutional landscape presents a more nuanced picture. SG Americas Securities dramatically increased its stake during the second quarter, expanding its position by a remarkable 741 percent to hold over 138,000 shares. This substantial commitment suggests that certain sophisticated investors remain confident in quantum computing’s long-term prospects despite current challenges.

Technical and Fundamental Crossroads

From a technical analysis perspective, Rigetti shares are approaching a critical juncture. The stock is nearing its 200-day moving average at $21.10, a key technical support level that traders watch closely. A sustained break below this threshold could potentially trigger another wave of selling.

Despite the reduced price targets, the average analyst recommendation remains at “Moderate Buy,” indicating that the long-term investment thesis may still be intact for many market observers. The successful commercial deployment of Rigetti’s announced 84-qubit Ankaa systems now takes on heightened importance. The company’s ability to translate this technological advancement into commercial success could prove pivotal for reversing the current negative momentum.

Ad

Rigetti Stock: Buy or Sell?! New Rigetti Analysis from February 7 delivers the answer:

The latest Rigetti figures speak for themselves: Urgent action needed for Rigetti investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Rigetti: Buy or sell? Read more here...

Tags: Rigetti
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
Dow Jones Stock

Can the Dow Jones Weather the Storm as Tech Stocks Falter?

Kraft Heinz Stock

Kraft Heinz Stock: Why Are the Smart Money Getting Out?

C3.ai Stock

C3.ai Shares Plunge to Alarming Lows

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com